Karsinoma Tiroid

01Pathophysiology

The thyroid gland contains two functionally distinct cell populations, and recognizing this is the foundation of understanding thyroid cancer. Follicular epithelial cells produce thyroid hormone and give rise to four of the five major cancer subtypes. Parafollicular C cells secrete calcitonin and give rise to medullary carcinoma. Each subtype follows a predictable pattern of behavior, spread, and prognosis dictated by its cell of origin and driver mutation.

Papillary thyroid carcinoma is the most common subtype and is driven primarily by BRAF V600E point mutations or RET/PTC rearrangements, both of which constitutively activate the MAPK signaling pathway. The defining behavior is lymphatic spread, which explains why patients so often present with cervical lymphadenopathy even when the primary tumor is small. Despite frequent nodal metastasis, the ten-year survival exceeds 95 percent. Pathognomonic histology includes "Orphan Annie eye" nuclei (empty, ground-glass appearance), nuclear grooves, intranuclear inclusions, and laminated calcifications called psammoma bodies.

Follicular thyroid carcinoma also originates from follicular cells but behaves quite differently. Driver mutations involve RAS or the PAX8/PPARγ fusion gene, and the tumor spreads hematogenously rather than through lymphatics. This produces distant metastases to lung and bone (often presenting as a pathologic fracture). A critical exam concept: fine needle aspiration cannot distinguish follicular adenoma from follicular carcinoma because the diagnosis requires demonstration of capsular or vascular invasion, which can only be assessed on a complete excised specimen.

Medullary thyroid carcinoma arises from neuroendocrine parafollicular C cells. Approximately 75 percent are sporadic, while 25 percent are hereditary as part of MEN 2A (medullary cancer, pheochromocytoma, parathyroid hyperplasia), MEN 2B (medullary cancer, pheochromocytoma, mucosal neuromas, marfanoid habitus), or familial medullary thyroid cancer. All hereditary forms involve germline RET proto-oncogene mutations. Because C cells secrete calcitonin, serum calcitonin serves as both a diagnostic marker and a postoperative surveillance tool. Histology reveals amyloid deposits that stain apple-green with Congo red under polarized light.

Anaplastic thyroid carcinoma represents the undifferentiated end of the spectrum, typically arising in elderly patients from a long-standing differentiated tumor that has accumulated additional mutations, particularly in TP53. It loses iodine uptake, thyroglobulin production, and TSH responsiveness. Clinically, it presents as a rapidly enlarging, stony-hard, fixed neck mass that invades the trachea and esophagus, producing airway compromise within weeks. Median survival is measured in months.

02Classification of Clinical Manifestations

03Diagnostic Workup

The workup begins with serum TSH, which is the single most important first step. If TSH is normal or elevated, proceed directly to thyroid ultrasound, which is the best initial imaging study and characterizes the nodule based on echogenicity, margins, calcifications, shape, and vascularity. Suspicious features include hypoechogenicity, microcalcifications, irregular margins, taller-than-wide shape, and extrathyroidal extension. Risk stratification systems (such as the ACR TI-RADS or ATA classification) translate these findings into a probability of malignancy and guide whether to biopsy.

If the TSH is suppressed (low), the workflow shifts. A low TSH suggests an autonomously functioning ("hot") nodule, which is rarely malignant. In this scenario, the next step is a radioiodine uptake scan, not biopsy. Hot nodules require management for hyperthyroidism rather than oncologic workup, while cold nodules (decreased uptake) require biopsy because roughly 15 percent are malignant.

Fine needle aspiration biopsy is the most accurate and confirmatory test for papillary, medullary, and anaplastic carcinomas. Cytology is reported using the Bethesda System (six categories ranging from non-diagnostic to malignant). The major exception is follicular neoplasm: FNA can identify follicular cells but cannot distinguish adenoma from carcinoma because that requires histologic evidence of capsular or vascular invasion. Therefore, indeterminate follicular lesions proceed to diagnostic lobectomy for definitive diagnosis.

For suspected medullary carcinoma, measure serum calcitonin and CEA, then obtain plasma fractionated metanephrines and serum calcium to rule out coexisting pheochromocytoma and primary hyperparathyroidism before any surgical intervention. Operating on a patient with an undiagnosed pheochromocytoma can precipitate a fatal hypertensive crisis. All patients with medullary carcinoma require RET germline testing, regardless of family history.

04Management and Treatment

Surgery is the foundation of treatment for nearly all thyroid cancers. The choice between lobectomy and total thyroidectomy depends on tumor size, histology, extrathyroidal extension, and nodal status. Recent guidelines permit lobectomy for unifocal differentiated tumors smaller than 1 cm without high-risk features. For tumors larger than 4 cm, those with extrathyroidal extension, or any medullary or anaplastic cancer, total thyroidectomy is mandatory. Central compartment neck dissection is added when clinically positive nodes are present and is routine for all medullary cancers.

After total thyroidectomy for differentiated thyroid cancer, radioactive iodine ablation is administered to destroy any remaining thyroid tissue and microscopic disease. This requires the residual tissue to be TSH-stimulated, achieved either by withdrawing levothyroxine for several weeks or by administering recombinant TSH. Doses range from 30 mCi for low-risk remnant ablation to 100-200 mCi for known metastatic disease. Pregnancy and breastfeeding are absolute contraindications to RAI; women must avoid conception for six to twelve months afterward.

Levothyroxine is then prescribed at a dose sufficient to suppress TSH, because TSH stimulates growth of any residual differentiated cancer cells. The target TSH depends on risk: less than 0.1 mU/L for high-risk patients, 0.1 to 0.5 mU/L for intermediate risk, and within the low-normal range for low-risk patients. Excessive suppression carries cardiac and skeletal risks, so the dose is individualized.

Medullary carcinoma does not respond to radioactive iodine because parafollicular C cells do not concentrate iodine. Treatment relies entirely on complete surgical resection. For locally advanced or metastatic disease, multikinase inhibitors such as vandetanib and cabozantinib improve progression-free survival, while selpercatinib and pralsetinib target RET-mutated tumors selectively with better tolerance. Postoperative surveillance uses calcitonin and CEA; rising calcitonin signals recurrence.

Anaplastic carcinoma demands urgent multimodal therapy. Airway protection comes first, sometimes requiring tracheostomy. Resectable disease is debulked, followed by external beam radiation and chemotherapy. For tumors harboring the BRAF V600E mutation (about 25 percent), dabrafenib plus trametinib has produced meaningful responses. Despite these advances, prognosis remains poor.

The next best step logic in vignettes typically follows this sequence: TSH first, then ultrasound, then FNA (if TSH normal) or radioiodine scan (if TSH suppressed), then surgery for malignant or indeterminate cytology, then RAI ablation and TSH suppression for differentiated cancer.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way examinees miss thyroid cancer questions is by skipping the TSH step and ordering biopsy or imaging first. Always anchor on the algorithm: TSH first, then ultrasound, then either FNA or radioiodine scan depending on whether TSH is normal or suppressed. A second classic pitfall is ordering an FNA on a follicular lesion and expecting a definitive answer; remember that follicular carcinoma diagnosis requires demonstration of capsular or vascular invasion, which mandates lobectomy. A third trap is forgetting to screen for pheochromocytoma before operating on medullary thyroid carcinoma; missing this step in the vignette is a frequent reason for losing the question.

Watch for the buzzwords. "Painless neck mass with cervical lymphadenopathy in a young woman" points to papillary cancer; "history of childhood radiation" is the strongest single risk factor mentioned in vignettes. "Pathologic fracture or lung metastases from a thyroid primary" points to follicular cancer because of its hematogenous spread. "Mucosal neuromas, marfanoid habitus, and a thyroid mass" is MEN 2B with medullary cancer. "Rapidly enlarging fixed neck mass with hoarseness in an elderly patient" is anaplastic carcinoma. "Hashimoto thyroiditis with sudden gland enlargement" is thyroid lymphoma, not anaplastic carcinoma, and is treated with chemotherapy rather than surgery.

The core competency being tested across these scenarios is twofold: first, sequencing the diagnostic workup correctly based on the TSH result, and second, matching the histologic and clinical pattern to the correct subtype so that management (surgery alone, surgery plus RAI, surgery plus genetic testing, or palliative multimodal therapy) follows logically. Mastering the cell of origin (follicular versus parafollicular C cells), the driver mutation, the spread pattern, and the tumor marker for each subtype lets you answer almost any question on this topic by deduction rather than recall.